ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
29 announcements
Jubilant Pharmova announced the USFDA classified their Spokane facility as 'Voluntary Action Indicated' (VAI) following a recent inspection. This concludes the inspection review process.
Jubilant Pharmova Limited received a GST show cause notice proposing a demand of ₹87.31 Crore. The demand includes tax, interest, and penalties for FY 2022-2023.
Jubilant Pharmova's subsidiary received a GST show-cause notice for Rs. 105.50 Crore. The company is contesting the demand involving GST and an equal penalty.
Jubilant Pharmova held its 48th Annual General Meeting on August 26, 2026, via video conferencing. Shareholders approved all agenda items, including the final dividend declaration.
Jubilant Pharmova received USFDA approval for commercial batch manufacturing on the new Line 3 at its Spokane, U.S.A. contract manufacturing facility.
Jubilant Pharmova shareholders approved the re-appointment of Mr. Priyavrat Bhartia as MD and Mr. Arjun Shanker Bhartia as Joint MD via postal ballot.
Jubilant Pharmova reported Q1 FY27 revenue of ₹2,229 Crore, reflecting 17% YoY growth. Net profit stood at ₹56 Crore amidst margin impacts.
Jubilant Pharmova Ltd reported revenue from operations of ₹2,229 Cr (+17.3% YoY) and net profit of ₹56.4 Cr (-45.0% YoY) for Q1 FY27.
Jubilant Pharmova Limited has issued a notice for its 48th Annual General Meeting, scheduled for August 26, 2026, including the annual report for FY 2025-26.
Jubilant Pharmova Limited has scheduled a Board Meeting on August 07, 2026, to consider and approve the standalone and consolidated financial results for the quarter ended June 30, 2026.
Jubilant Pharmova informed the stock exchanges regarding the communication sent to shareholders concerning the transfer of unclaimed shares and dividends to the IEPF Authority.
Jubilant Pharmova Ltd filed its quarterly shareholding pattern for the period ending June 30, 2026. The filing details the distribution of equity shares across various categories.
Jubilant Pharmova has issued a Postal Ballot Notice seeking shareholder approval for the re-appointment of its Managing Director and Joint Managing Director.
Jubilant Pharmova approved the grant of 2,07,003 Stock Options, RSUs, and PSUs. The exercise prices range from Re. 1 to Rs. 974.45 per share.
Jubilant Pharmova received a rectification order deleting a Rs. 22.10 crore tax demand for AY 2020-21. Separate appeals on other grounds remain pending before ITAT.
Jubilant Pharmova received a tax rectification order disallowing Rs.53.37 Crore in brought forward losses. The company intends to appeal the decision.
Jubilant Pharmova's subsidiary received a tax rectification order reducing adjustments to ₹42.41 Crore. This provides a tax relief of ₹65.48 Crore.
Jubilant Pharmova received a USFDA Warning Letter for its Montreal facility following an inspection. Operations continue under enhanced oversight while the company initiates corrective remediation actions.
Jubilant Pharmova Limited filed its Annual Secretarial Compliance Report for FY 2025-26. The report confirms overall regulatory compliance with no material deviations or fines noted.
Jubilant Pharmova Q4FY26 revenue grew 19% YoY to ₹2,290 Cr. FY26 revenue reached ₹8,280 Cr (up 14%) driven by CDMO Sterile Injectables and Radiopharma growth.
Jubilant Pharmova recommended a final dividend of ₹5 per equity share for 2026. The record date is set for July 24, 2026, awaiting shareholder approval.
Jubilant Pharmova's subsidiary received a Rs. 107.89 Crore income tax demand order. The company intends to appeal, anticipating no material financial impact post-adjudication.
Jubilant Pharmova reported FY26 revenue of ₹8,280 Crore, a 14% YoY increase. Growth was driven by the CDMO Sterile Injectables segment and expanded Ruby-Fill® installations.
Jubilant Pharmova approved the re-appointment of Mr. Priyavrat Bhartia and Mr. Arjun Shanker Bhartia for three-year terms. These appointments ensure leadership continuity for upcoming years.
Jubilant Pharmova appointed Ashish Mukkirwar as CFO effective May 23, 2026. He succeeds Arun Kumar Sharma, who transitions to an advisory role following his resignation.
Jubilant Pharmova Ltd reported revenue from operations of ₹2,290 Cr (+18.7% YoY) and net profit of ₹119.3 Cr (-21.2% YoY) for Q4 FY26.
Jubilant Pharmova reported audited FY26 financial results and recommended a 500% final dividend of ₹5 per share. Totaling ₹79.6 Crore, payment follows shareholder approval.
Jubilant Pharmova Ltd has scheduled a Board Meeting on May 22, 2026. The directors will consider and approve audited standalone and consolidated financial results for the year ended March 31, 2026, and evaluate a final dividend recommendation.
Jubilant Pharmova Limited has scheduled a Board Meeting for May 22, 2026. The Board will consider the audited standalone and consolidated financial results for the year ended March 31, 2026, and recommend a final dividend. The trading window is closed from April 1, 2026, until May 24, 2026.